№ lp_2_3_67319
File format: docx Character count: 82566 File size: 395 KB
This document is a submission for the inclusion of Vorasidenib in the Australian General Schedule for the treatment of IDH-mutant astrocytoma or oligodendroglioma.
Year: 2023
Region / city: Australia
Theme: Pharmaceutical regulation
Document type: Submission for listing
Agency: SERVIER LABORATORIES (AUST.) PTY. LTD.
Author: Unspecified
Target audience: Medical professionals
Effective period: From 11 September 2023
Approval date: 11 September 2023
Date of changes: N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.